[⁶⁸Ga]Ga-PSMA-11 uptake in planepitheliale lung cancer: a pitfall in prostate cancer imaging

Prostate cancer (PCa) is the second most frequent cancer diagnosis made in men and the fifth leading cause of death worldwide [1]. Prostate-specific membrane antigen labeled with gallium 68 ([⁶⁸Ga]Ga-PSMA-11) is a promising radiotracer frequently used in diagnostics of the patients with biochemical recurrence of PCa. PSMA’s expression in non-small cell lung cancer (NSCLC) ranks around 16%, while tumor neovasculature expression is seen in 59% of tumor samples and is dependent on NSCLC histopathological type. The highest (71%) is seen in large cell carcinoma (LCC) and in squamous cell carcinoma (SCC) – 64%, while the lowest (45%) is noted in adenocarcinoma (AC) [2] [3].

Publication History

Received: 12 August 2022

Accepted after revision: 15 December 2022

Article published online:
31 January 2023

• References

• 1 Bray F, Ferlay J, Soerjomataram I. et al. Global Cancer Statistics, 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca Cancer J Clin 2018; 68: 394-424
• 2 Schmidt LH, Heitkötter B, Schulze AB. et al. Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer. PLoS One 2017; 12: e0186280
• 3 Wang HL, Wang S, Song W. et al. Expression of prostate-specific membrane antigen in lung cancer cells and tumor neovasculature endothelial cells and its clinical significance. PLoS One 2015; 10: e0125924
• 4 Jochumsen MR, Gormsen LC, Nielsen GL. 68Ga-PSMA Avid Primary Adenocarcinoma of the Lung With Complementary Low 18F-FDG Uptake. Clin Nucl Med 2018; 43: 117-119
• 5 Usmani S, Sadeq A, Marafi F. et al. 68Ga-PSMA Uptake in the Lung: Metastatic Versus Primary Lung Tumor. Clin Nucl Med 2020; 45: e80-e82